CDKN1B and breast carcinoma: Interestingly, the recently developed liposomal:peptide drug NP-ALT has shown the ability to suppress the tyrosine phosphorylation-mediated inhibition of p27KIP1 and to induce necroptosis and tumor regression in xenograft models of breast cancer [58], pointing to p27KIP1 as an effective anticancer target.